78 completed, 35 recruiting, 27 terminated, 26 active not recruiting. 189 Phase 2, 37 Phase 1, 6 Phase 3.
Follow enzalutamide: new trials by email Literature Review of enzalutamide trials Research Report on enzalutamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) Sacituzumab tirumotecan, Rescue medication, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 290 | 2026-12-14 | 2026-11-02 |
| A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer. ADT plus abiraterone or other ARPIs(apalutamide, enzalutamide, rezvilutamide, darolutamide) - Metastatic Hormone-Sensitive Prostate Cancer | Phase 2 | Not yet recruiting | Anhui Medical University | 40 | 2026-10-01 | 2026-08-31 |
| Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) tinengotinib 10 mg QD plus darolutamide, tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide, tinengotinib 10 mg QD plus enzalutamide - Prostate Cancer (CRPC) | Phase 2 | Recruiting | TransThera Sciences (Nanjing), Inc. | 182 | 2026-09-18 | 2026-10-13 |
| A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy Mevrometostat, Enzalutamide - Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate Cancer (Adenocarcinoma) | Phase 2 | Not yet recruiting | Prostate Cancer Clinical Trials Consortium | 60 | 2026-08-01 | 2026-05-18 |
| Study of XNW5004 Tablets in Advanced Prostate Cancer XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone, XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone, XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID - Advanced Prostate Cancer | Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 242 | 2026-07-13 | 2026-07-28 |
| Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-06-01 | 2026-05-05 |
| A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide Talazoparib with enzalutamide, Talazoparib - Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 2 | Recruiting | Prostate Cancer Clinical Trials Consortium | 126 | 2026-05-04 | 2026-08-21 |
| A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer Inavolisib, Enzalutamide, Abiraterone - Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | Hoffmann-La Roche | 100 | 2026-03-11 | 2026-11-06 |
| A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer HS-20093 for Injection, SHR3680 Tablet, Abiraterone Tablet - Prostate Cancer | Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 218 | 2025-12-08 | 2026-03-03 |
| A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC AMO959, AAA617, Enzalutamide - PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 123 | 2025-12-05 | 2026-10-15 |
| A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer QLC5508, abiraterone acetate, enzalutamide - Advanced Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 212 | 2025-11-05 | 2026-06-02 |
| Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer QLH12016, abiraterone acetate, enzalutamide - Prostatic Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 50 | 2025-10-01 | 2025-08-05 |
| The COSMYC Trial (COmbined Suppression of MYC) ZEN-3694, Testosterone cypionate, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2025-08-19 | 2026-10-30 |
| Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC) TYK-00540, Enzalutamide - mCRPC | Phase 1 / Phase 2 | Not yet recruiting | TYK Medicines, Inc | 48 | 2025-08-01 | 2025-08-05 |
| An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) JSB462, Abiraterone, Enzalutamide - Metastatic Hormone-sensitive Prostate Cancer | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 168 | 2025-07-07 | 2026-11-13 |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 360 | 2025-07-03 | 2026-10-09 |
| Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer ADT, Enzalutamide, Talazoparib - Prostate Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2025-06-03 | 2026-11-02 |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 474 | 2025-02-06 | 2026-11-03 |
| Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer Luteinizing Hormone-Releasing Hormone (LHRH) analog, Androgen Receptor Signal Inhibitor (ARSI), Docetaxel - Metastatic Castration Sensitive Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 25 | 2025-01-10 | 2026-04-01 |
Showing 20 of 189. Sign in to see all of them.
Prostatic Neoplasms (108) · Breast Neoplasms (12) · Neoplasm Metastasis (10) · Prostatic Neoplasms, Castration-Resistant (10) · Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (5) · Triple Negative Breast Neoplasms (4) · Adenocarcinoma (3) · Melanoma (3) · Squamous Cell Carcinoma of Head and Neck (3) · COVID-19 (2) · Carcinoma, Hepatocellular (2) · Endometrial Neoplasms (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (9) · Pfizer (8) · Astellas Pharma Global Development, Inc. (6) · National Cancer Institute (NCI) (6) · Memorial Sloan Kettering Cancer Center (5) · Astellas Pharma Inc (4) · M.D. Anderson Cancer Center (4) · Bayer (3) · British Columbia Cancer Agency (3) · Dana-Farber Cancer Institute (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Institute of Cancer Research, United Kingdom (3) · Merck Sharp & Dohme LLC (3) · Novartis Pharmaceuticals (3) · OHSU Knight Cancer Institute (3)
United States (131) · Spain (25) · Canada (24) · United Kingdom (22) · Australia (16) · China (16) · Italy (16) · France (13) · Belgium (10) · Germany (10) · Netherlands (9) · South Korea (9) · Brazil (7) · Ireland (7) · Japan (7)
Samuel Denmeade, MD (5) · Jingsong Zhang, MD, PhD (3) · Kim N Chi, MD (3) · Ravi A Madan, M.D. (3) · Anthony D Elias, MD (2) · Edwin Posadas, MD FACP (2) · Johann De Bono, MD (2) · Mary-Ellen Taplin, MD (2) · Michael Schweizer (2)
PMID 22894553, PMID 25687533, PMID 25937426, PMID 30189902, PMID 32923850, PMID 11905923, PMID 18423743, PMID 18777528, PMID 18930581, PMID 18990168, PMID 19097774, PMID 19359544, PMID 19399748, PMID 19455472, PMID 19996060, PMID 20116997, PMID 20398925, PMID 21859989, PMID 22452894, PMID 22747660, PMID 23063623, PMID 23096187, PMID 23163774, PMID 23228172, PMID 23671006, PMID 23813930, PMID 23910941, PMID 23999218, PMID 24258798, PMID 24321502, PMID 24510426, PMID 24590644, PMID 24739897, PMID 24772219, PMID 24881730, PMID 24882673, PMID 25104109, PMID 25184630, PMID 25354111, PMID 25888263, PMID 25985882, PMID 26343110, PMID 26718929, PMID 26719232, PMID 26774508, PMID 26793974, PMID 26811535, PMID 27068431, PMID 27497762, PMID 28300506
2023 (6), 2019 (4), 2014 (3), 2015 (3), 2017 (3), 2016 (2), 2025 (2), 2004 (1), 2018 (1), I01CX002277 (1), P01CA203628 (1), P30CA014089 (1), P30CA014599 (1), P30CA015704 (1), P30CA022453 (1)